Haleon (NYSE:HLN) Posts Earnings Results

Haleon (NYSE:HLN) released its earnings results on Thursday. The company reported $0.05 earnings per share for the quarter, Zacks reports. Haleon had a return on equity of 14.76% and a net margin of 10.85%.

Haleon Trading Down 3.9 %

Shares of Haleon stock traded down $0.40 during mid-day trading on Thursday, hitting $9.81. The stock had a trading volume of 5,812,522 shares, compared to its average volume of 10,253,093. The firm has a 50-day moving average of $9.58 and a two-hundred day moving average of $9.83. The firm has a market cap of $44.39 billion, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon has a 12-month low of $7.89 and a 12-month high of $10.80.

Analyst Upgrades and Downgrades

HLN has been the subject of several research reports. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haleon has a consensus rating of “Moderate Buy” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.